Imke H Bartelink1, Rada M Savic, Grant Dorsey, Theodore Ruel, David Gingrich, Henriette J Scherpbier, Edmund Capparelli, Vincent Jullien, Sera L Young, Jane Achan, Albert Plenty, Edwin Charlebois, Moses Kamya, Diane Havlir, Francesca Aweeka. 1. From the Department of *Clinical Pharmacy, †Bioengineering & Therapeutic Sciences, ‡Medicine, and §Pediatrics, and ¶Center for AIDS Prevention Studies of the University of California, San Francisco, CA; ‖Department of Pediatric Immunology and Infectious Diseases, Emma Children's Hospital AMC, The Netherlands; **University of California San Diego, La Jolla, CA; ††Department of Pharmacology, Hôpital Européen Georges Pompidou, Paris Descartes, France; ‡‡Division of Nutritional Sciences, Cornell University, Ithaca, NY; and Departments of §§Pediatrics and Child Health, and ¶¶Medicine, Makerere University, Kampala, Uganda.
Abstract
BACKGROUND: Malnutrition may impact the pharmacokinetics (PKs) of antiretroviral medications and virologic responses in HIV-infected children. The authors therefore evaluated the PK of nevirapine (NVP), efavirenz (EFV) and lopinavir (LPV) in associations with nutritional status in a cohort of HIV-infected Ugandan children. METHODS: Sparse dried blood spot samples from Ugandan children were used to estimate plasma concentrations. Historical PK data from children from 3 resource-rich countries (RRC) were utilized to develop the PK models. RESULTS: Concentrations in 330 dried blood spot from 163 Ugandan children aged 0.7-7 years were analyzed in reference to plasma PK data (1189 samples) from 204 children from RRC aged 0.5-12 years. Among Ugandan children, 48% was malnourished (underweight, thin or stunted). Compared to RRC, Ugandan children exhibited reduced bioavailability of EFV and LPV; 11% (P=0.045) and 18% (P=0.008), respectively. In contrast, NVP bioavailability was 46% higher in Ugandan children (P<0.001) with a trend toward greater bioavailability when malnourished. Children receiving LPV, EFV or NVP had comparable risk of virologic failure. Among children on NVP, low height and weight for age Z scores were associated with reduced risk of virologic failure (P=0.034, P=0.068, respectively). CONCLUSIONS: Ugandan children demonstrated lower EFV and LPV and higher NVP exposure compared to children in RRC, perhaps reflecting the consequence of malnutrition on bioavailability. In children receiving NVP, the relation between exposure, malnutrition and outcome turned out to be marginally significant. Further investigations are warranted using more intensive PK measurements and adequate adherence assessments, to further assess causes of virologic failure in Ugandan children.
BACKGROUND:Malnutrition may impact the pharmacokinetics (PKs) of antiretroviral medications and virologic responses in HIV-infectedchildren. The authors therefore evaluated the PK of nevirapine (NVP), efavirenz (EFV) and lopinavir (LPV) in associations with nutritional status in a cohort of HIV-infected Ugandan children. METHODS: Sparse dried blood spot samples from Ugandan children were used to estimate plasma concentrations. Historical PK data from children from 3 resource-rich countries (RRC) were utilized to develop the PK models. RESULTS: Concentrations in 330 dried blood spot from 163 Ugandan children aged 0.7-7 years were analyzed in reference to plasma PK data (1189 samples) from 204 children from RRC aged 0.5-12 years. Among Ugandan children, 48% was malnourished (underweight, thin or stunted). Compared to RRC, Ugandan children exhibited reduced bioavailability of EFV and LPV; 11% (P=0.045) and 18% (P=0.008), respectively. In contrast, NVP bioavailability was 46% higher in Ugandan children (P<0.001) with a trend toward greater bioavailability when malnourished. Children receiving LPV, EFV or NVP had comparable risk of virologic failure. Among children on NVP, low height and weight for age Z scores were associated with reduced risk of virologic failure (P=0.034, P=0.068, respectively). CONCLUSIONS: Ugandan children demonstrated lower EFV and LPV and higher NVP exposure compared to children in RRC, perhaps reflecting the consequence of malnutrition on bioavailability. In children receiving NVP, the relation between exposure, malnutrition and outcome turned out to be marginally significant. Further investigations are warranted using more intensive PK measurements and adequate adherence assessments, to further assess causes of virologic failure in Ugandan children.
Authors: Wiete Kromdijk; Jan W Mulder; Hilde Rosing; Patrick M Smit; Jos H Beijnen; Alwin D R Huitema Journal: J Antimicrob Chemother Date: 2012-02-01 Impact factor: 5.790
Authors: Yuan Ren; James J C Nuttall; Claire Egbers; Brian S Eley; Tammy M Meyers; Peter J Smith; Gary Maartens; Helen M McIlleron Journal: J Acquir Immune Defic Syndr Date: 2007-06-01 Impact factor: 3.731
Authors: Daniel González de Requena; Francisco Blanco; Teresa Garcia-Benayas; Inmaculada Jiménez-Nácher; Juan González-Lahoz; Vincent Soriano Journal: AIDS Patient Care STDS Date: 2003-09 Impact factor: 5.078
Authors: Paolo Denti; Anneke C Hesseling; Louvina E van der Laan; Anthony J Garcia-Prats; H Simon Schaaf; Tjokosela Tikiso; Lubbe Wiesner; Mine de Kock; Jana Winckler; Jennifer Norman; Helen McIlleron Journal: Antimicrob Agents Chemother Date: 2018-01-25 Impact factor: 5.191
Authors: Catherine A Koss; Paul Natureeba; Dorcas Nyafwono; Albert Plenty; Julia Mwesigwa; Bridget Nzarubara; Tamara D Clark; Theodore D Ruel; Jane Achan; Edwin D Charlebois; Deborah Cohan; Moses R Kamya; Diane V Havlir; Sera L Young Journal: J Acquir Immune Defic Syndr Date: 2016-03-01 Impact factor: 3.731
Authors: Thomas P C Dorlo; Anke E Kip; Brima M Younis; Sally J Ellis; Fabiana Alves; Jos H Beijnen; Simon Njenga; George Kirigi; Asrat Hailu; Joseph Olobo; Ahmed M Musa; Manica Balasegaram; Monique Wasunna; Mats O Karlsson; Eltahir A G Khalil Journal: J Antimicrob Chemother Date: 2017-11-01 Impact factor: 5.790